China Securities Journal (Wang Luo) - On November 11, Anke Biotechnology...The company announced on its official WeChat account that it has signed a Capital Increase Agreement and an Exclusive Agency Framework Agreement with Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., establishing a new round of in-depth strategic cooperation. According to the agreements, Anke Biotechnology , as Boshengji's second-largest shareholder, will invest an additional 30 million yuan to increase Boshengji's capital. Simultaneously, Anke will leverage its commercial advantages to obtain the exclusive nationwide distribution rights for Boshengji's core product, PA3-17 injection. This move marks a formal upgrade from early R&D cooperation and equity investment to a comprehensive strategic partnership based on "capital binding and joint business operation."
　　This collaboration revolves around Boshengji's core investigational product—PA3-17 injection, the world's first Investigational New Drug (IND) approved product targeting CD7 autologous CAR-T cells. Developed independently by Boshengji Anke Cell Technology Co., Ltd., a wholly-owned subsidiary of Boshengji, this product innovatively employs a non-gene editing strategy, effectively solving industry challenges related to CAR-T cell cannibalization and tumor cell contamination during PA3-17 injection preparation. A new quality control system has also been established. Phase I registration clinical trial results showed that PA3-17 injection demonstrated good safety and outstanding efficacy in patients with relapsed/refractory T-ALL and T-LBL. Currently, PA3-17 injection has been included in the Breakthrough Therapy List of the Center for Drug Evaluation (CDE) of the National Medical Products Administration and has entered the pivotal Phase II clinical trial stage, with its market launch imminent.
　　Anke Biotechnology stated that as a major shareholder of Boshengji, the company has a long-standing cooperative relationship with the company. Anke Biotechnology was not only an early strategic investor in Boshengji, but the two companies had also previously established a strong foundation for cooperation in cell therapy research and development through their joint venture, "Boshengji Anke." This capital increase and the signing of the exclusive agency framework agreement further extend the company's collaboration beyond R&D to the commercialization stage. According to the agreement, in addition to PA3-17 injection, Anke Biotechnology will also have priority agency rights for other innovative products launched by Boshengji in the future. This move expands from a single product to the entire CAR-T product pipeline, building a long-term partnership for future cooperation.
　　Industry insiders say that Anke Biotechnology, with its nationwide mature marketing system and commercialization experience, will provide strong support for the rapid market penetration of PA3-17 injection. This dual-track model of "capital increase + exclusive agency" not only paves a "fast track" for Boshengji's product launch but also reflects Anke Biotechnology's forward-looking strategy in innovative drug development.The two parties share a strategic commitment to leveraging capital and commercialization capabilities to help cutting-edge technologies move from the laboratory to the market. This deepened cooperation is expected to inject crucial momentum into independent innovation and commercialization in China's CAR-T cell therapy field.

https://finance.eastmoney.com/a/202511113561267994.html